Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Approves VEGF Trap-Eye for Wet AMD: Bayer Healthcare
November 21, 2011
- GSK, Daiichi Sankyo Launch Rotarix for Prevention of Rotavirus Gastroenteritis in Children
November 21, 2011
- CMIC to Establish Holding Company “CMIC HD”
November 18, 2011
- “Steady Sales in 1st Half as Result of Strict Price Lock System Operation”: President Hamada of Toho HD
November 18, 2011
- Bayer to Expand Asian Business, Focus on Chinese Market
November 18, 2011
- Teva to Merge Taiyo, Kowa-Teva, Establish “Teva Pharma Japan” in Mid-2012
November 18, 2011
- Intellim Corp. to Strengthen Contract Research System in Field of Oncology
November 18, 2011
- BMKK Applies for Add’l Indications for Taxol Based on Data in Public Domain
November 18, 2011
- Kyowa Pharm. to Buy I’rom Pharm. to Boost Sales to DPC Hospitals
November 18, 2011
- Nippon Shinyaku Grants Marketing Rights for Gaslon N･OD Tablets to Taejoon in ROK
November 18, 2011
- Meiji Seika Pharma Applies for Add’l Indications for Viccilin Based on Data in Public Domain
November 18, 2011
- Eli Lilly Japan to Provide Alimta for Free for IIT
November 18, 2011
- Fujifilm, Kyowa Kirin to Set Up Joint Venture for Biosimilars in 2012
November 17, 2011
- Takeda Initiates PII Trials of Inactivated Poliovirus, Combined 4-valent Vaccine TAD-361S in Japan
November 17, 2011
- Synix to Establish Oncology Market Research Division in December
November 17, 2011
- Zeria Aims at 50% Domestic Market Share for UC Treatment Asacol in FY2011
November 17, 2011
- High Court’s Ruling in Iressa Appeal “Extremely Fair and Reasonable”: Attorney for AZ
November 16, 2011
- Survey Finds 33% Pharmacists and Pharmacy Students Know “Established Drugs”
November 16, 2011
- Anticancer Drug SyB L-0501 Starts PII Trial for Refractory, Relapsed Multiple Myeloma (MM): SymBio
November 16, 2011
- MEDINET Initiates Clinical Study of DC Vaccine
November 16, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…